Search results for "ibi"

showing 10 items of 13473 documents

Analysis of platelet function and dysfunction.

2014

SummaryAlthough platelets act as central players of haemostasis only their cross-talk with other blood cells, plasma factors and the vascular compartment enables the formation of a stable thrombus. Multiple activation processes and complex signalling networks are responsible for appropriate platelet function. Thus, a variety of platelet function tests are available for platelet research and diagnosis of platelet dysfunction. However, universal platelet function tests that are sensitive to all platelet function defects do not exist and therefore diagnostic algorithms for suspected platelet function disorders are still recommended in clinical practice.Based on the current knowledge of human p…

0301 basic medicineBlood PlateletsPlatelet Function TestsPlatelet dysfunctionPoint-of-care testingPoint-of-Care SystemsVascular compartment030204 cardiovascular system & hematologySensitivity and Specificity03 medical and health sciences0302 clinical medicineThrombinmedicineHumansPlateletThrombusbusiness.industryReproducibility of ResultsHematologymedicine.disease030104 developmental biologyPlatelet function testImmunologyBlood Platelet DisordersbusinessFunction (biology)medicine.drugHamostaseologie
researchProduct

The potential of cystatin C as a predictive biomarker in breast cancer

2020

Breast cancer (BCa) is the leading cause of cancer-related deaths among women. Numerous efforts are being directed toward identifying novel tissue and/or circulating molecular markers that may help clinicians in detecting early-stage BCa patients and in providing an accurate estimation of the prognosis and prediction of response to clinical treatments. In this setting, emerging evidence has indicated Cystatin C (Cyst C), as the most potent endogenous inhibitor of cysteine cathepsins, as a possible useful marker in the clinical management of BCa patients.This review analyzes the results of emerging studies underpinning a potential clinical role of Cyst C, as additional marker in BCa.Cyst C e…

0301 basic medicineBreast NeoplasmsMetastasiCysteine proteinaseMetastasisCathepsin03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerBiomarkers Tumorproteinase inhibitorMedicineAnimalsHumansPharmacology (medical)Cystatin Cskin and connective tissue diseasesPredictive biomarkerNeoplasm StagingCathepsinbiologybusiness.industryTumor progressionjCystatin C CystatinCysteine proteinasesmedicine.diseasePrognosis030104 developmental biologyOncologyCystatin CTumor progression030220 oncology & carcinogenesistumor markerCancer researchbiology.proteinDisease ProgressionFemalebusiness
researchProduct

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.

2020

Gastric cancer (GC) represents the fifth cause of cancer-related death worldwide. Molecular biology has become a central area of research in GC and there are currently at least three major classifications available to elucidate the mechanisms that drive GC oncogenesis. Further, tumor microenvironment seems to play a crucial role, and tumor-associated macrophages (TAMs) are emerging as key players in GC development. TAMs are cells derived from circulating chemokine- receptor-type 2 (CCR2) inflammatory monocytes in blood and can be divided into two main types, M1 and M2 TAMs. M2 TAMs play an important role in tumor progression, promoting a pro-angiogenic and immunosuppressive signal in the tu…

0301 basic medicineCCR2ChemokineAngiogenesismedicine.medical_treatmentAngiogenesis Inhibitorsmedicine.disease_cause03 medical and health sciences0302 clinical medicineAntineoplastic Agents ImmunologicalStomach NeoplasmsmedicineTumor MicroenvironmentAnimalsHumansRadiology Nuclear Medicine and imagingMolecular Targeted TherapyTumor microenvironmentClinical Trials as Topicbiologybusiness.industryMacrophagesCancerGeneral MedicineImmunotherapymedicine.disease030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisCancer researchbiology.proteinDisease ProgressionCarcinogenesisbusinessCancer treatment reviews
researchProduct

CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular d…

2017

IF 1.886; International audience; Background: The wet form of age-related macular degeneration (AMD) is characterized by pathological vascularization of the outer retinal layers. The condition responds to treatment with antibodies against vascular endothelial growth factor (VEGF), but the patients receiving such anti-VEGF therapy sometimes show undesirable acute short-term increases in the intraocular pressure (IOP). The cause of this adverse effect is unknown, and here, we are testing a hypothesis that it is related to CD36 gene polymorphisms.Materials and Methods: A group of 134 patients with AMD were given three therapeutic doses of anti-VEGF antibody (ranibizumab) at monthly intervals. …

0301 basic medicineCD36 AntigensMaleVascular Endothelial Growth Factor AIntraocular pressuregenetic structuresreceptorGlaucomaAngiogenesis InhibitorsthrombospondinPolymerase Chain Reactionpolymorphismchemistry.chemical_compound0302 clinical medicineGenotypeGenetics (clinical)Schlemm´s canalVascular endothelial growth factorIntravitreal InjectionsFemalemedicine.drugmedicine.medical_specialtyPolymorphism Single Nucleotide03 medical and health sciencesTonometry Ocular[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyOphthalmologyRanibizumabmedicineHumansAdverse effectIntraocular PressureAgedbusiness.industryGlaucomaRetinalMacular degenerationmedicine.diseaseeye diseasesOphthalmology030104 developmental biologychemistryPediatrics Perinatology and Child Health030221 ophthalmology & optometryWet Macular DegenerationOcular Hypertensionsense organsRanibizumabbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyOphthalmic genetics
researchProduct

Wheat amylase-trypsin inhibitors exacerbate intestinal and airway allergic immune responses in humanized mice.

2017

Background Amylase-trypsin inhibitors (ATIs) in wheat and related cereals are potent activators of myeloid innate immune cells via engagement of TLR4. Furthermore, ATIs have been shown to serve as adjuvants in experimental intestinal inflammatory diseases. Objective The aim of this study was to analyze whether ATIs are also modifiers of allergic inflammation. Methods Therefore, CD4 + T cells from donors sensitized to grass or birch pollen were stimulated with autologous allergen-pulsed dendritic cells in the presence or absence of ATIs or the control storage protein zein from corn. To analyze allergen-induced gut and lung inflammation, immunodeficient mice were engrafted with PBMCs from the…

0301 basic medicineCD4-Positive T-LymphocytesMaleAllergyTHP-1 Cellsmedicine.medical_treatmentImmunologyInflammationOmalizumabImmunoglobulin EAllergic inflammation03 medical and health sciencesMice0302 clinical medicineImmune systemImmunology and AllergyMedicineAnimalsHumansTriticumPlant ProteinsMice KnockoutInnate immune systembiologybusiness.industryfood and beveragesmedicine.diseaseAsthmaImmunity Innate030104 developmental biologyCytokineImmunologyAmylasesbiology.protein030211 gastroenterology & hepatologyFemalemedicine.symptombusinessTrypsin Inhibitorsmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

The iNOS Activity During an Immune Response Controls the CNS Pathology in Experimental Autoimmune Encephalomyelitis

2019

Inducible nitric oxide synthase (iNOS) plays a critical role in the regulation of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Previous studies have shown that iNOS plays pathogenic as well as regulatory roles in MS and EAE. However, how does iNOS alters the pathophysiology of the central nervous system (CNS) in neuronal autoimmunity is not clearly understood. In the present work, we show that treatment of mice with L-NAME, an iNOS inhibitor, during the antigen-priming phase primarily alters brain pathology, while in the subsequent effector phase of the immune response, the spinal cord is involved. Inhibition of iNOS during the priming phase of the immune res…

0301 basic medicineCD4-Positive T-LymphocytesPathologyexperimental autoimmune encephalomyelitisNitric Oxide Synthase Type IIApoptosismedicine.disease_causeAutoimmunityMice0302 clinical medicineImmunology and AllergyEnzyme InhibitorsOriginal ResearchMice KnockoutbiologyExperimental autoimmune encephalomyelitisautoimmunityCell DifferentiationNitric oxide synthaseOligodendrogliamedicine.anatomical_structureNG-Nitroarginine Methyl EsterIntegrin alpha Mlcsh:Immunologic diseases. Allergymedicine.medical_specialtyEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisLymphoid TissueCentral nervous systemImmunology03 medical and health sciencesInterferon-gammaImmune systemmedicineAnimalsHumansNOS2−/− neuroinflammationNeuroinflammationbusiness.industryMultiple sclerosisinducible nitric oxide synthaseDendritic Cellsmedicine.diseasecentral nervous systemMice Inbred C57BL030104 developmental biologybiology.proteinbusinesslcsh:RC581-607030215 immunologyGranulocytesFrontiers in Immunology
researchProduct

Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis

2017

Objectives: To understand the role of macrophage migration inhibitory factor (MIF) in the pathogenesis of Ankylosing Spondylitis (AS). Methods: AS patients satisfying the modified New York criteria were recruited for the study. Healthy volunteers, rheumatoid arthritis and osteoarthritis patients were included as controls. Based on the annual rate of increase in mSASSS scores, AS patients were classified as progressors or non-progressors. MIF levels were quantitated by ELISA in the serum and synovial fluid. Predictors of AS progression were studied by logistic regression analysis. Immunohistochemistry of ileal tissue was performed to identify MIF producing cells. Flow cytometry was used to r…

0301 basic medicineCD74animal diseasesImmunologychemical and pharmacologic phenomenaInflammationPathogenesis03 medical and health sciences0302 clinical medicineRheumatologyotorhinolaryngologic diseasesmedicineImmunology and AllergySynovial fluid030203 arthritis & rheumatologyAnkylosing spondylitisbusiness.industryrespiratory systemmedicine.diseasebiological factors3. Good health030104 developmental biologyRheumatoid arthritisImmunologyMacrophage migration inhibitory factorTumor necrosis factor alphamedicine.symptombusinessArthritis & Rheumatology
researchProduct

The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells.

2018

PTPRJ, a receptor protein tyrosine phosphatase strongly downregulated in human cancer, displays tumor suppressor activity by negatively modulating several proteins involved in proliferating signals. Here, through a proteomic-based approach, we identified a list of potential PTPRJ-interacting proteins and among them we focused on CD98hc, a type II glycosylated integral membrane protein encoded by SLC3A2, corresponding to the heavy chain of a heterodimeric transmembrane amino-acid transporter, including LAT1. CD98hc is widely overexpressed in several types of cancers and contributes to the process of tumorigenesis by interfering with cell proliferation, adhesion, and migration. We first valid…

0301 basic medicineCD98hcChemistryCell growthCellPTPRJProtein tyrosine phosphatasemedicine.disease_causeProtein tyrosine phosphatase03 medical and health scienceschemistry.chemical_compound030104 developmental biologymedicine.anatomical_structureProteasomal degradationOncologyMG132Cancer cellCancer researchmedicineProteasome inhibitorGene silencingLung cancerCarcinogenesismedicine.drugResearch Paper
researchProduct

Behavioural and structural interventions in cancer prevention: towards the 2030 SDG horizon

2020

Interventions in individual lifestyles have often been viewed as the main component of cancer prevention strategies. However, environmental factors may facilitate or impede healthy behaviours. The behavioural‐structural dichotomy of cancer prevention can only be resolved by incorporating the ‘Health in All Policies’ perspective at multiple levels (legislation, promotion of healthy choices, health support groups, health education).

0301 basic medicineCancer ResearchAgenda 2030health promotionHealth BehaviorPsychological interventionContext (language use)lcsh:RC254-28203 medical and health sciences0302 clinical medicineRisk FactorsNeoplasmsGeneticsHumansMoral responsibilitySocial determinants of healthLife StyleCancer preventionPolicy Articlesstructural interventionsPublic economicscancer preventionhealth in all policiesGeneral MedicineProtective FactorsSustainable Developmentsustainable development goalslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyHealth promotionOncology030220 oncology & carcinogenesisPolicy ArticleMolecular MedicineHealth educationbehavioural interventionsPsychologynoncommunicable disease preventionUrbanismMolecular Oncology
researchProduct

Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines

2015

Abstract Somatic mutations binding to the patient's MHC and recognized by autologous T cells (neoepitopes) are ideal cancer vaccine targets. They combine a favorable safety profile due to a lack of expression in healthy tissues with a high likelihood of immunogenicity, as T cells recognizing neoepitopes are not shaped by central immune tolerance. Proteins mutated in cancer (neoantigens) shared by patients have been explored as vaccine targets for many years. Shared (“public”) mutations, however, are rare, as the vast majority of cancer mutations in a given tumor are unique for the individual patient. Recently, the novel concept of truly individualized cancer vaccination emerged, which explo…

0301 basic medicineCancer ResearchBioinformaticsmedicine.disease_causeMajor histocompatibility complexCancer VaccinesEpitopeTranslational Research BiomedicalEpitopesGenetic Heterogeneity03 medical and health sciences0302 clinical medicineAntigenAntigens NeoplasmNeoplasmsAnimalsHumansMedicineClinical Trials as TopicMutationbiologybusiness.industryGenetic heterogeneityGenetic VariationCancermedicine.diseaseAntigenic VariationVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisMutationbiology.proteinCancer vaccinebusinessClinical Cancer Research
researchProduct